Chronic Kidney Disease Market: Five Emerging Therapies Set to Transform Treatment by 2036

Disc Medicine completed a Phase I study in healthy volunteers and advanced DISC-0974 into further clinical development. The company has initiated a Phase Ib/II study in patients with myelofibrosis-associated anemia and a Phase II study in patients with inflammatory bowel disease-associated anemia. Although these programs extend beyond CKD-specific treatment, the candidate illustrates the broader importance of addressing anemia and related complications in chronic disease management. Its relevance to CKD will depend on further clinical development and evidence in appropriate patient populations.

Download the report to understand the top chronic kidney disease drugs manufacturer @ https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Conclusion

The chronic kidney disease treatment landscape is poised for continued development as innovative therapies address unmet needs beyond conventional kidney-protective medicines. AstraZeneca's zibotentan/dapagliflozin, Boehringer Ingelheim's vicadrostat plus empagliflozin, ProKidney's rilparencel, Mineralys Therapeutics' lorundrostat, and Disc Medicine's DISC-0974 represent different approaches to kidney protection, hormonal regulation, and complication management. Their ultimate impact will depend on clinical outcomes, safety, regulatory decisions, and accessibility. Alongside earlier diagnosis and combination treatment strategies, these developments could reshape competition and create new opportunities across the chronic kidney disease market through 2036.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

info@delveinsight.com